Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-05-05Clinical Trial Update: Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy [Phase 1, Phase 2]
Open-label Phase I/Randomized, Double-Blind Phase II study evaluating AZD5363 in combination with DP chemotherapy for metastatic castration-…
-
CLINICAL_TRIALS trial_result · 2022-04-15Clinical Trial Update: Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel [Phase 2, Phase 3]
A completed Phase 2/3 trial update evaluating the optimal sequencing of treatments for poor-risk metastatic castration-resistant prostate ca…
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Pamiparib in mCRPC With HRD or BRCA1/2 Mutation [Phase 2]
Phase 2 trial update for pamiparib in metastatic castration-resistant prostate cancer with HRD or BRCA1/2 mutation.
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies [Phase 2]
Phase 2 trial update reporting efficacy and safety data for Niraparib in men with metastatic castration-resistant prostate cancer and DNA-re…
-
CLINICAL_TRIALS trial_result · 2022-03-04Clinical Trial Update: Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial comparing Abiraterone Acetate tablets with ZYTIGA in metastatic castration-resistant prostate cancer has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation [Phase 2]
Phase 2 study evaluating olaparib in newly diagnosed metastatic castration-resistant prostate cancer patients with HRR gene mutations.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic [Phase 2]
Phase 2 trial evaluating treatment of metastatic castration-resistant prostate cancer using circulating tumor cell kinetics.
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer [Phase 2]
Phase 2 study evaluating nivolumab in combination with rucaparib, docetaxel, or enzalutamide in metastatic castration-resistant prostate can…
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC [Phase 2]
Phase 2 trial update assessing Avelumab plus a second-generation androgen deprivation therapy in African American men with metastatic castra…
-
CLINICAL_TRIALS trial_result · 2021-12-16Clinical Trial Update: Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment [Phase 2]
Phase 2 trial update on senaparib in metastatic castration-resistant prostate cancer patients with homologous recombination repair gene alte…
-
CLINICAL_TRIALS trial_result · 2021-12-15Clinical Trial Update: A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone [Phase 3]
Phase 3 trial evaluating whether continuing enzalutamide beyond progression improves outcomes for men with metastatic castration-resistant p…
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial evaluating TQB3616 capsules in combination with abiraterone acetate plus prednisone for metastatic castration-resista…
-
CLINICAL_TRIALS trial_result · 2021-11-17Clinical Trial Update: Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency [Phase 2]
Phase 2 trial studying treatment of metastatic castration-resistant prostate cancer with homologous recombination deficiency has been termin…
-
CLINICAL_TRIALS trial_result · 2021-10-14Clinical Trial Update: Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
Clinical trial update for avelumab in combination with bempegaldesleukin with or without talazoparib or enzalutamide in advanced solid tumor…
-
CLINICAL_TRIALS trial_result · 2021-10-01Clinical Trial Update: Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 trial exploring sirolimus combined with docetaxel and carboplatin in metastatic castration-resistant prostate cancer; the study st…
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. [Phase 2]
Phase 2 trial comparing an alternative antiandrogen therapy with early initiation of enzalutamide in castration-resistant prostate cancer af…
-
CLINICAL_TRIALS trial_result · 2021-09-09Clinical Trial Update: The Combination Therapy With Ra-223 and Enzalutamide [Phase 2]
Phase 2 trial update on combining Ra-223 with Enzalutamide for castration-resistant prostate cancer with bone metastases.
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer [Phase 1]
Phase 1 dose-escalation and dose-expansion trial of GSK525762 in combination with androgen deprivation therapy in castration-resistant prost…
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 3]
Phase 3 trial evaluating apalutamide in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone for ch…
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 3]
Phase 3 efficacy and safety study update on apalutamide plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in…
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating ZEN003694 in combination with enzalutamide for metastatic castration-resistant prostate cancer has comple…
-
CLINICAL_TRIALS trial_result · 2021-07-30Clinical Trial Update: Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluated cabazitaxel with or without carboplatin in patients with previously treated metastatic castration-resistant pros…
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer [Phase 2]
Phase 2 trial of NRX 194204 in castration- and taxane-resistant prostate cancer has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-04-30Clinical Trial Update: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen [Phase 3]
Phase 3 trial evaluating atezolizumab in combination with enzalutamide for metastatic castration-resistant prostate cancer after AR pathway …
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease. [Phase 2]
A Phase II study evaluating enzalutamide and ARv7 in metastatic castration-resistant prostate cancer with visceral metastases has completed.